TOP 20 Top 20 RNAi Therapeutic Companies Based on 2022 R&D ExpenditureByPrince GiriApril 25, 20230Comments
VIEWPOINTS Bettina Cockroft, SVP & CMO at Sangamo Therapeutics Shares Insights from the Positive P-I/II Data for Fabry Disease TreatmentBySenior EditorApril 24, 20230Comments
VIEWPOINTS Paul K Owens, VP of Global Brand Development, Insulins & Glucagon at Eli Lilly & Company Shares Insights from the US FDA Approval of LyumjevBySenior EditorApril 20, 20230Comments
INSIGHTS+ Insights+: The US FDA New Drug Approvals in March 2023BySenior EditorApril 19, 20230Comments
VIEWPOINTS James Graham, CEO of Recce Pharmaceuticals Shares Insights from the Expansion and Acceleration of Clinical ProgramsBySenior EditorApril 18, 20230Comments
VIEWPOINTS Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of SotyktuBySenior EditorApril 17, 20230Comments
INSIGHTS+ Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)BySenior EditorApril 13, 20230Comments
